Integra LifeSciences Holdings Co. (NASDAQ:IART) Chairman Stuart Essig Acquires 52,641 Shares of Stock

Integra LifeSciences Holdings Co. (NASDAQ:IART) Chairman Stuart Essig acquired 52,641 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was purchased at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the transaction, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock traded down $0.20 during trading on Friday, reaching $28.31. The company’s stock had a trading volume of 814,733 shares, compared to its average volume of 1,529,534. The firm has a market cap of $2.23 billion, a PE ratio of 56.62, a P/E/G ratio of 1.03 and a beta of 1.17. The company has a 50-day moving average price of $30.53 and a two-hundred day moving average price of $37.35. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15. Integra LifeSciences Holdings Co. has a fifty-two week low of $22.36 and a fifty-two week high of $46.75.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The company had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. During the same period in the previous year, the business posted $0.74 earnings per share. Integra LifeSciences’s quarterly revenue was down 3.2% on a year-over-year basis. On average, analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its holdings in shares of Integra LifeSciences by 181.1% during the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock worth $4,427,000 after buying an additional 80,463 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Integra LifeSciences by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,421 shares of the life sciences company’s stock valued at $1,256,000 after purchasing an additional 2,114 shares in the last quarter. Quadrature Capital Ltd boosted its holdings in Integra LifeSciences by 81.6% in the 1st quarter. Quadrature Capital Ltd now owns 27,354 shares of the life sciences company’s stock valued at $969,000 after purchasing an additional 12,290 shares in the last quarter. Capital Research Global Investors boosted its holdings in Integra LifeSciences by 37.7% in the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in Integra LifeSciences by 191.0% in the 1st quarter. EntryPoint Capital LLC now owns 4,580 shares of the life sciences company’s stock valued at $162,000 after purchasing an additional 3,006 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

IART has been the topic of several recent analyst reports. Bank of America cut their price target on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 7th. Wells Fargo & Company lowered Integra LifeSciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $45.00 to $25.00 in a research report on Tuesday, May 7th. JMP Securities lowered their price target on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a report on Tuesday, May 7th. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Finally, Citigroup upped their target price on shares of Integra LifeSciences from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $35.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.